April 2, 2026 European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
April 2, 2026 Vaginal Yeast Infections Treatment Market to Reach USD 7.7 Billion by 2036, Driven by Rising Awareness, OTC Adoption
April 2, 2026 Shrub Oak International School Highlights Founders Pillar Curriculum: A Comprehensive Five-Pillar Approach for Autistic Students with Complex Needs
April 2, 2026 Engine and Nuqleous Complete Strategic Merger: Creating an End-to-End Omnichannel Retail Intelligence Platform for CPGs
